I grew up around cigarettes in Germany and watched them vanish. Bans, taxes, and warning labels on sugary drinks all work differently, and what separates them is not how much soda drops. It is who they reach.
Two dozen outlets ran the same glucosamine-Alzheimer’s scare in four days. The new Nature Metabolism paper is strong mouse biology with a weak hospital-records footnote, and the bigger human data points the other way.
Federal researchers buried a study showing no safe level of drinking. The red-wine myth, and what alcohol quietly costs your sleep, testosterone, blood pressure, and training recovery after 50.
The drugs were ordinary. The result wasn’t: a 27-point blood-pressure drop in men medicine usually fails to reach. A colleague mentioned this interesting hypertension treatment project to me almost in passing, so I looked up the study. A group in Los Angeles turned Black barbershops into blood pressure clinics. Men came in for haircuts and,
I have spent the last year and a half watching my own bloodwork change, and the number that moved the most was not the one I expected. My LDL cholesterol improved, which I was working on. But the marker that fell off a cliff was my hs-CRP, a measure of low-grade inflammation in the body.
After 50, better sleep came down to two boring things: enough hours and a steady schedule. What a year of my own Apple Watch data and the evidence showed.
The American Cancer Society just added a blood test and new stool tests to its colon cancer screening guideline. Why colonoscopy still wins, what each option misses, and how to choose.
I inject myself a few times a week now, GLP-1 and TRT, and barely notice. The needle, not the drug, is the real barrier in modern health, and it is starting to fall.
A new Cell Metabolism paper connects creatine to depression through the gut microbiome. The effect is real, but it shows up only in clinically diagnosed depressed patients who are already on antidepressants. The dose-creep crowd is about to ignore that distinction.
Huberman talks about it, Bryan Johnson takes it, Goop sells it, Walgreens stocks it. After months of hearing the NAD+ pitch repeated, I still could not tell whether it was a breakthrough or snake oil. Two new human studies gave me the clearest answer I have read.
